Health organizations have questions, but few answers about feds’ new $5-billion Health Infrastructure Fund
The Canadian Association for Long Term Care says it will need an additional 382,400 to 454,000 beds by 2035 to keep up with demand. This is an increase of between 93 per cent and 121 per cent.
‘It’s like molasses in January’: pharmacare implementation stalled, say health-care groups, but others argue time needed to get deals right
Only British Columbia, Manitoba, Prince Edward Island, and the Yukon have reached pharmacare deals with the federal government, covering contraception and diabetes medications.
When a parliamentary committee recently politicized EDI in research, they put Canadian science and patient care at risk
Equity, diversity, and inclusion policies do not compete with research excellence, but instead strengthen it.
Canada’s reliance on U.S. health data under spotlight after federal health minister says she ‘cannot trust’ American vaccine policy
Canadian Public Health Association’s Ian Culbert says the U.S. used to be a trustworthy source, but Canada now needs to ‘up our game’ on health data, while a former PHAC bureaucrat says analyzing data from other jurisdictions is a part of the job.
Five affordable ways to improve access to health care in 2026
Governments must find ways to reduce restrictions on where doctors can practise and barriers for international medical graduates, improve health data system, create AI guidelines, and lessen the health system’s carbon footprint.
CUSMA must do more than protect trade—it must secure Canada’s life sciences future
The U.S. may begin to apply tariffs or other barriers to enhance its domestic production, and if that happens, Canada will need a plan not just to respond, but also to thrive.
Alberta’s health-care reforms don’t go far enough
If the Smith government allowed private ‘urgent care’ and family care, it could open the door for innovation and personalization.
PHAC lacks timely national data on children’s vaccination rates as report finds agency is not meeting targets
The agency’s 2024-25 departmental results report uses rates from a 2021 survey. Newer data is available, but that source doesn’t include rates from all provinces and territories.
Redesigning Canada’s health policy to spur innovation
When patents create an unbalanced system of protection, regulatory exclusivities, which safeguard a firm’s data from being copied by competitors while still allowing scientific collaboration, offer a better alternative.
PMPRB closes all open drug-pricing investigations before implementing new guidelines on Jan. 1
But that doesn’t mean the drug pricing tribunal can’t look at past years’ data to inform future reviews of drug prices, says director general Guillaume Couillard.
